Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 4:48 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1153–1176 of 12,238 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Multiple Diseases Clear all

Conditions: Bladder Cancer
Interventions: BCG delivery at home; Other
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Rheumatoid Arthritis
Interventions: adalimumab, Placebo; Drug
Lead sponsor: Abbott; Industry
Eligibility: 18 Years and older
Enrollment: 420 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 48
States / cities: Huntsville, Alabama • Tuscaloosa, Alabama • Paradise Valley, Arizona + 44 more

Conditions: Multiple Myeloma
Interventions: Cyclophosphamide, Ixazomib, Dexamethasone; Drug
Lead sponsor: Millennium Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 148 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 6
States / cities: Hazard, Kentucky • Boston, Massachusetts • Rochester, Minnesota + 3 more

Conditions: Traumatic Brain Injury
Interventions: PNT001, %5 dextrose for infusion; Biological
Lead sponsor: Pinteon Therapeutics, Inc; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: HIV Infections
Interventions: Entre Culturas: Navigating Culture, Identity, and HIV Risk; Behavioral
Lead sponsor: Nova Southeastern University; Other
Eligibility: 18 Years to 29 Years · Male only
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Osteoarthritis, Knee
Interventions: Atlas(TM) Knee System; Device
Lead sponsor: Moximed; Industry
Eligibility: 25 Years to 80 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 9
States / cities: Phoenix, Arizona • Greenwood, Indiana • Boston, Massachusetts + 6 more

Conditions: Atrial Fibrillation
Interventions: Not listed
Lead sponsor: Thrombosis Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 57,250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2020
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Parkinson Disease
Interventions: CVL-751; Drug
Lead sponsor: Cerevel Therapeutics, LLC; Industry
Eligibility: 45 Years to 75 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 2
States / cities: Long Beach, California • Atlanta, Georgia

Conditions: Fever, Neutropenia
Interventions: Low Risk: Oupatient Management, Low Risk: Inpatient Management, High Risk: Inpatient Management; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 0 Years to 21 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Non-Hodgkin's Lymphoma
Interventions: Iodine I 131 Tositumomab; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2007
U.S. locations: 6
States / cities: Bay Pines, Florida • Chicago, Illinois • Ann Arbor, Michigan + 3 more

Conditions: Chronic Inducible Urticaria, Cold Urticaria, Cold-Induced Urticaria, Symptomatic Dermographism
Interventions: Barzolvolimab, Matching Placebo; Drug
Lead sponsor: Celldex Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 26
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Bakersfield, California + 22 more

Conditions: Carcinoma, Renal Cell
Interventions: GW786034, lapatinib; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 21 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Carcinoma, Renal Cell
Interventions: GW786034; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 21 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005
U.S. locations: 5
States / cities: Little Rock, Arkansas • Boston, Massachusetts • Durham, North Carolina + 2 more

Conditions: Myelodysplastic Syndrome
Interventions: Azacitidine for Injection, Vidaza®; Drug
Lead sponsor: Bioniche Pharma USA LLC; Industry
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 4
States / cities: Anaheim, California • Corona, California • Fresno, California + 1 more

Conditions: Hypertension
Interventions: Darusentan, Darusentan Placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 35 Years to 80 Years
Enrollment: 352 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 67
States / cities: Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 62 more

Conditions: Anxiety Disorder, Breast Cancer, Depression, Fatigue, Hot Flashes, Pain, Sleep Disorders
Interventions: acupuncture therapy, sham intervention; Procedure
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years and older · Female only
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 2
States / cities: Baltimore, Maryland

Conditions: Female Sexual Arousal Disorder
Interventions: Sildenafil, Placebo; Drug
Lead sponsor: Strategic Science & Technologies, LLC; Industry
Eligibility: 21 Years and older · Female only
Enrollment: 440 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 51
States / cities: Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 45 more

Conditions: Depressive Disorder, Treatment-Resistant
Interventions: MIJ821, Placebo, Ketamine; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 8
States / cities: Birmingham, Alabama • Garden Grove, California • Oakland, California + 5 more

Conditions: Stage I Breast Cancer, Stage II Breast Cancer, Stage III Breast Cancer, Invasive Breast Cancer
Interventions: Vorinostat and Tamoxifen; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older · Female only
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Down Syndrome
Interventions: Speech therapy addressing phonology and motor learning; Behavioral
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 7 Years to 16 Years · Male only
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Multiple Sclerosis (MS)
Interventions: elezanumab, placebo; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 208 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 42
States / cities: Birmingham, Alabama • Phoenix, Arizona • Berkeley, California + 35 more

Conditions: Painful Peripheral Diabetic Neuropathy
Interventions: Provant Therapy System; Device
Lead sponsor: Regenesis Biomedical, Inc.; Industry
Eligibility: 22 Years to 80 Years
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Scottsdale, Arizona

Conditions: Pediatric Obesity, Pediatric Overweight
Interventions: Multifamily weight management intervention; Behavioral
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 8 Years to 17 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Colorectal Cancer, Non-small Cell Lung Carcinoma (Adenocarcinoma), Triple Negative Breast Cancer, Renal Cell Carcinoma
Interventions: PDR001, LCL161, Everolimus, Panobinostat, QBM076, HDM201; Biological · Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 298 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 9
States / cities: Santa Monica, California • Baltimore, Maryland • Boston, Massachusetts + 6 more

Search by objective public record fields.

Intravesical Treatment of Bladder Cancer at Home, Multi-modal Treatment Support

Study Comparing 80 mg of Adalimumab With Placebo, and Demonstrating the Non-inferiority of Monthly 80 mg Adalimumab Dosing Compared With 40 mg Adalimumab Every Other Week Dosing

Phase 2 Study to Evaluate the Oral Combination of Ixazomib (MLN9708) With Cyclophosphamide and Dexamethasone in Patients With Newly Diagnosed or Relapsed and/or Refractory Multiple Myeloma

Safety and Tolerability of PNT001 in Patients With Acute Traumatic Brain Injury (TBI)

Motiv82Change: an HIV Prevention Study for Young Latino Men

Atlas Knee System Clinical System Clinical Study (USA)

Global Anticoagulant Registry in the Field

A 2-Part Trial of CVL-751 in Subjects With Parkinson's Disease

Fever and Neutropenia in Pediatric Oncology Patients

Study of Untreated or Transformed Follicular Non-Hodgkin's Lymphoma With Fission-Derived Iodine I 131 Tositumomab

A Study to Investigate Efficacy, Safety and Tolerability of Barzolvolimab Versus Placebo in Adults With Cold Induced Urticaria and Symptomatic Dermographism Inadequately Controlled by H1-antihistamines (EMBARQ - ColdU and SD)

Study Of Safety And Tolerability Of GW786034 Given With Lapatinib In Cancer Patients

Pazopanib (GW786034) In Subjects With Relapsed Or Refractory Multiple Myeloma

Bioequivalence Study of Azacitidine for Injection in Myelodysplastic Syndrome (MDS) Patients

DORADO - Fixed Doses of Darusentan as Compared to Placebo in Resistant Hypertension

Acupuncture in Reducing Muscle and Bone Symptoms in Women Receiving Letrozole, Exemestane, or Anastrozole for Stage 0, Stage I, Stage II, or Stage III Breast Cancer

Multi-Center Study to Evaluate the Efficacy and Safety of Sildenafil Cream (3.6%) in Premenopausal Patients With Female Sexual Arousal Disorder

Proof of Concept Study Evaluating the Efficacy and Safety of MIJ821 in Patients With Treatment-resistant Depression

A Study of Vorinostat and Tamoxifen in Newly Diagnosed Breast Cancer

Down Syndrome Speech Intelligibility Diagnostic Treatment Study

A Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard of Care in Relapsing Forms of Multiple Sclerosis

Nociceptive Pain Fiber Response

Reducing Barriers to Behavior Change Among Youth With Pediatric Overweight and Obesity

A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat